Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Shulman

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
American Journal of Public Health|November 1, 1989
The broader message of accutaneS R Shulman
Pharmacoeconomics|December 10, 1991
The reimbursement factor in pharmaceutical regulation: rebates, cost-effectiveness, and practice guidelinesS R Shulman
Pharmacoeconomics|December 9, 1993
The Canadian Patented Medicine Prices Review Board. New rules and new statusS R Shulman
Hospital Formulary|December 11, 1987
Drug refusal must include legal definition of competenceS R Shulman
Pharmacoeconomics|December 8, 1997
Pharmacy benefit management companies (PBMs). Why should we be interested?S R Shulman
Pharmacoeconomics|December 9, 1995
Healthcare reform in the US. Momentum shifts from federal to state governmentsS R Shulman
Pharmacoeconomics|August 5, 1997
The US orphan drug programme 1983-1995S R Shulman, M Manocchia
Journal of Theoretical Biology|January 7, 1980
An evolutionary model of female dominance relations in primatesB Chapais, S R Shulman
Pharmacoeconomics|March 9, 1993
Therapeutic substitution: an option for cost-effective prescribing?S R Shulman, W Gouveia
Journal of Clinical Pharmacology|July 1, 1990
FDA regulations provide broader access to unapproved drugsS R Shulman, D S Raiford
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
American Journal of Public Health|November 1, 1989
The broader message of accutaneS R Shulman
Pharmacoeconomics|December 10, 1991
The reimbursement factor in pharmaceutical regulation: rebates, cost-effectiveness, and practice guidelinesS R Shulman
Pharmacoeconomics|December 9, 1993
The Canadian Patented Medicine Prices Review Board. New rules and new statusS R Shulman
Hospital Formulary|December 11, 1987
Drug refusal must include legal definition of competenceS R Shulman
Pharmacoeconomics|December 8, 1997
Pharmacy benefit management companies (PBMs). Why should we be interested?S R Shulman
Pharmacoeconomics|December 9, 1995
Healthcare reform in the US. Momentum shifts from federal to state governmentsS R Shulman
Pharmacoeconomics|August 5, 1997
The US orphan drug programme 1983-1995S R Shulman, M Manocchia
Journal of Theoretical Biology|January 7, 1980
An evolutionary model of female dominance relations in primatesB Chapais, S R Shulman
Pharmacoeconomics|March 9, 1993
Therapeutic substitution: an option for cost-effective prescribing?S R Shulman, W Gouveia
Journal of Clinical Pharmacology|July 1, 1990
FDA regulations provide broader access to unapproved drugsS R Shulman, D S Raiford
Pageof 2